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Abstract
Aims/hypothesis The relationship between BMI and mortality
has been extensively investigated in the general population;
however, it is less clear in people with type 2 diabetes. We
aimed to assess the association of BMI with all-cause and
cardiovascular mortality in individuals with type 2 diabetes
mellitus.
Methods We searched electronic databases up to 1March 2016
for prospective studies reporting associations for three or more
BMI groups with all-cause and cardiovascular mortality in in-
dividuals with type 2 diabetes mellitus. Study-specific associa-
tions between BMI and the most-adjusted RR were estimated
using restricted cubic splines and a generalised least squares
method before pooling study estimates with a multivariate
random-effects meta-analysis.
Results We included 21 studies including 24 cohorts, 414,587
participants, 61,889 all-cause and 4470 cardiovascular
incident deaths; follow-up ranged from 2.7 to 15.9 years.
There was a strong nonlinear relationship between BMI and
all-cause mortality in both men and women, with the lowest
estimated risk from 31–35 kg/m2 and 28–31 kg/m2 (p value
for nonlinearity <0.001) respectively. The risk of mortality at
higher BMI values increased significantly only in women,
whilst lower values were associated with higher mortality in
both sexes. Limited data for cardiovascular mortality were
available, with a possible inverse linear association with
BMI (higher risk for BMI <27 kg/m2).
Conclusions/interpretation In type 2 diabetes, BMI is
nonlinearly associated with all-cause mortality with lowest
risk in the overweight group in both men and women.
Further research is needed to clarify the relationship with
cardiovascular mortality and assess causality and sex differences.
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Introduction
Compared with the general population, diabetes mellitus is
associated with a higher mortality, mainly attributable to
cardiovascular causes [1]. In 2012, an estimated 1.5 million
deaths were directly caused by diabetes and by 2030 diabetes
is expected to be the seventh leading cause of death worldwide
[2]. Being overweight or obese is one of the main modifiable
risk factors for type 2 diabetes mellitus, and obesity has been
significantly associated with an increased mortality risk in the
general population [3]. However, evidence on the association
between obesity and mortality in patients with diabetes
remains inconclusive with some studies reporting an inverse
association between obesity (estimated using the conventional
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measure of BMI) and mortality [4–6], some reporting
U-shaped associations [7, 8], some reporting linear positive
associations [9, 10], and some reporting no association [11].
A recent study investigating the relationship between BMI
and mortality in 10,568 people with type 2 diabetes found a
lower mortality risk in overweight (BMI ≥25 kg/m2), higher
mortality risk in underweight (≤18.5 kg/m2), and a similar
mortality risk in obese (BMI ≥30 kg/m2) people compared
with those with normal weight, indicating a nonlinear
association between BMI and all-cause mortality [12]. A
recent systematic review including nine studies reported a
reduced risk of all-cause mortality in overweight and obese
people with type 2 diabetes when compared with normal or
non-overweight people and a 5% progressive decrease in
mortality for every 5 kg/m2 increase in BMI [13]. This
analysis, however, did not explore whether a nonlinear
relationship exists between BMI and outcomes. This is
particularly relevant, given the possible presence of
nonlinearity for BMI values within the category of overweight
or obesity. Moreover, a clearer determination of the
relationship across BMI values would elucidate the
comparative relevance of higher and lower BMI values on
mortality risk in people with diabetes.
To help clarify the evidence, we conducted a systematic
review and meta-analysis of prospective studies to examine
the shape of association of BMI with all-cause and
cardiovascular mortality in individuals with type 2 diabetes
mellitus.
Methods
This meta-analysis was performed following the Meta-analysis
Of Observational Studies in Epidemiology (MOOSE)
recommendations [14].
Data sources, searches and study selection Three
independent investigators searched for prospective studies
reporting associations between BMI and all-cause and
cardiovascular mortality in people with type 2 diabetes
mellitus using the databases PubMed, Web of Science, and
Scopus. The search strategy combined keywords related to
the exposure (i.e. ‘obesity’ OR ‘body mass index’ OR
‘BMI’), population (i.e. ‘diabetes’ OR ‘type 2 diabetes’),
outcome (i.e. ‘cardiovascular’ OR ‘vascular’ OR ‘mortality’)
and study design (i.e. ‘cohort’ OR ‘longitudinal’) and
included articles published in English before 1 March 2016
(details of the search strategy are reported in the electronic
supplementary material [ESM]). Reference lists of retrieved
articles were also manually scanned for all relevant additional
studies and reviews. Prospective studies were included if the
RR of cardiovascular or all-cause mortality was reported for at
least three BMI categories (one referent and two nonreferent).
When multiple publications reported associations from the
same cohort, we included the one with the longest follow-up
or the largest sample size. We excluded studies including only
participants with type 1 diabetes, or only participants with
prevalent cardiovascular disease at baseline, or hospitalised
patients. If studies reported estimates stratified by prevalent
cardiovascular disease at baseline, we used data for
participants without baseline cardiovascular disease.
Data extraction and quality assessment We used
standardised, pre-defined forms for data extraction and quality
assessment. We abstracted data on first author name; year of
journal publication; study location and follow-up duration;
population age, source, sex distribution; baseline prevalence
of cardiovascular disease; exposure definition and assessment;
endpoint definition and ascertainment; and adjustment level.
For each reported category of BMI, we collected data on:
mean or median BMI value; number of participants (or
person-years of follow-up); number of cases; and the RR with
95% CI. If category-specific mean or median BMI was not
reported, we assumed the BMI value to be the midpoint
between lower and upper boundaries; if one boundary was
not reported in the first or last category, we assumed the
difference between boundaries to be equal to that of the
adjacent category. When studies published more than one
adjusted RR, we extracted the most-adjusted estimate. When
reported, we extracted data separately for men and women.
We contacted study authors when it was not possible to extract
data from published reports. Study quality was assessed by
two authors using the nine-star Newcastle–Ottawa Scale
(NOS) [15] and discrepancies were resolved by consensus or
independent arbitration.
Data synthesis and analysis
For each outcome, we extracted RRs with 95% CIs for men,
women and both. When studies only reported association
separately for men and women, a within-study summary
estimate was computed by fixed-effect meta-analysis. A
similar summary estimate was calculated for one study
reporting associations stratified by age. To assess the
relationship between BMI and outcomes, we performed a
two-stage random-effects dose–response meta-analysis
[16–18]. In the first stage, we modelled BMI values using
restricted cubic splines with three knots at 10%, 50% and
90% percentile of the BMI distribution. We then estimated
study-specific trend between RRs and the two BMI spline
transformations with a generalised least squares method,
which accounts for the correlation within each set of RRs
[16]. In the second stage, the two study-specific regression
coefficients were combined in a multivariate random-effects
meta-analysis using the restricted maximum likelihood
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method [19]. We used coefficients obtained from multivariate
meta-analysis to perform a Wald-type test for the hypothesis
of no exposure–disease association (both regression
coefficients equal to zero) and of nonlinearity (second spline
coefficient equal to zero) [20]. We assessed heterogeneity be-
tween sexes with a multivariate meta-regression. Publication
bias was estimated with the Egger’s test [21]. We conducted a
sensitivity analysis excluding studies that only report
unadjusted effect estimates to assess whether the associations
between BMI and mortality change. Furthermore, the
association between BMI and several chronic conditions has
been reported to vary in different demographic regions; there-
fore we also assessed whether there was any statistically sig-
nificant heterogeneity in the association between BMI and
mortality by regions (USA, Europe and UK, Asia) using mul-
tivariate meta-regression and also stratified the analysis by
regions. In addition, use of medications may affect the mortal-
ity risk, and considering the changes in the guidelines for the
management of diabetes and use of glucose-lowering therapies
over the study period we conducted a multivariate meta-
regression categorising the study periods as 2003–2010,
2011–2013, 2014–2015) to assess whether there were signifi-
cant differences in the effect estimates by the time of the study.
We also performed additional sensitivity analyses with three
knots at different positions (e.g. 25th, 50th and 75th percentile)
to assess whether the shape of the association changed.
Analyses were performed using Stata 14.1 [22, 23] and R
[24, 25]. Two-sided p value <0.05 was considered statistically
significant.
Results
Study characteristics Our initial search yielded 38,615
articles. After screening of title/abstract and exclusion of
duplicates, 70 articles remained for further evaluation
(Fig. 1). Following detailed assessments, and after the
inclusion of three articles identified from manual searches,
21 articles were included in the quantitative analysis
(21 studies and 24 unique cohorts; Table 1) [7, 8, 11, 15,
26–42]. Study characteristics and theNOS scores are provided
in ESM Tables 1–3. Out of the 21 studies included, ten (48%)
had an NOS score of 8, whilst two (10%) studies had NOS
scores of 9 or 5, indicating that most of the studies included
were of good or high quality. Overall, information was
available for 414,587 male and female participants with
61,889 and 4470 incident all-cause and cardiovascular
mortality events, respectively. In nine studies associations
were reported separately for men and women (Table 1). The
mean (or median) duration of follow-up ranged from 2.7 to
15.9 years and the mean baseline age ranged from 40 to
77 years. All but three studies adjusted for age and sex
(when appropriate) and diagnosis of diabetes was mainly
self-reported or based on biochemical measurements (ESM
Tables 1 and 2). Ten studies (47.6%) with 214,694 participants
(51.8%) included people from the USA or UK, whilst seven
studies were from elsewhere in Europe, one multinational, and
one each from Iran, South Korea, and Taiwan.
All-cause mortality Overall, 18 studies comprising 407,270
participants and 60,815 all-cause death events were included
in the analysis; study-specific associations are reported in
ESM Figs 1–3. As shown in Fig. 2, there was an overall
nonlinear relationship between BMI and all-cause mortality
(p value for no exposure–disease association <0.001; p value
for nonlinearity <0.001). The lowest risk was at BMI around
33 kg/m2, with an increased mortality risk more evident for
lower than higher BMI values. Although no statistically
significant heterogeneity was found (p=0.376), the shape of
the relationships differed between men and women. In the
analysis restricted to men (nine studies, 141,709 participants/
24,230 events), the lowest risk was between 31 and 35 kg/m2,
with an increased risk for values lower than 31 kg/m2 and a
slightly non-significant increase for values higher than 35 kg/
m2 (p value for no exposure–disease association 0.0034; p
value for nonlinearity 0.001). Conversely, almost a symmetri-
cal increase was evident for women (eight studies, 168,088
participants/25,061 events) with a BMI nadir around 28–
31 kg/m2 (p value for no exposure–disease association
<0.001; p value for nonlinearity <0.001).
For the three analyses, there was evidence of heterogeneity
across studies (ESM Table 4) but not of publication bias
(p values 0.403; 0.521; and 0.550, respectively).
Cardiovascular mortality Six studies comprising 98,309
participants reported data on BMI and 4291 cardiovascular
incident deaths for both men and women (Table 1 and ESM
Fig. 4). The overall shape of the association suggested an
increased risk of cardiovascular mortality for values lower
than 27 kg/m2 and a less clear association for higher values
(p value for no exposure–disease association 0.0176; p value
for nonlinearity 0.140) (Fig. 3). However, a reduced risk for
values greater than 27 kg/m2 and a possible linear negative
trend cannot be excluded (RR per unit increase of BMI: 0.98;
95%CI: 0.96, 0.99; p = 0.013). No publication bias was
present (p=0.258). Owing to the limited number of studies,
it was not possible to stratify the analysis by sex.
Sensitivity analyses The results were consistent with those of
the main analysis after the exclusion of two studies reporting
unadjusted estimates, yet the risk of all-cause death for high
values of BMI in women was less pronounced (ESM Table 5
and ESM Fig. 5). No heterogeneity was found in stratified
analyses by region (USA, Europe and UK, Asia; p=0.069)
or period (2003–2009, 2011–2013, 2014–2015; p=0.117)
(ESM Table 6 and ESM Fig. 6). Results were substantially
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similar in sensitivity analyses considering alternative knot
locations (ESM Fig. 7 and ESM Fig. 8).
Discussion
Results of this meta-analysis indicate a clear nonlinear
relationship between BMI and all-cause mortality, with the
lowest risk found around 33 kg/m2 and an increased risk more
evident for lower compared with higher values. The shape of
the association between BMI and all-cause mortality,
however, was found to be different between male and female
participants such that the risk did not increase for values
higher than 35 kg/m2 in men whilst a symmetrical rise was
found in women above and below a nadir around 28–31 kg/m2.
Conversely, the limited data availability for cardiovascular
mortality precluded a clear interpretation of the relationship,
particularly for high values of BMI.
Our meta-analysis is the largest to-date to assess the
association between BMI and mortality among people with
diabetes. However, there are certain limitations of this study.
First, most of the included studies adjusted risk estimates for a
number of potential confounders; only five, however, adjusted
for alcohol consumption, which is closely associated with
mortality and BMI [43, 44]. Cardiorespiratory fitness has been
reported as a potential effect modifier in the association of
BMI and mortality, suggesting a ‘fit and fat’ phenomenon
whereby higher cardiorespiratory fitness attenuates the
increased mortality risk associated with higher BMI [45].
Given the available data, we could not explore this hypothesis
in our meta-analysis. Similarly, we could not assess the impact
of fat distribution, another possible effect modifier in the
relationship between BMI and outcomes. Indeed, recent
research has suggested that fat distribution is more strongly
associated than BMI to future cardiovascular events risk [46].
Possible confounders of the association are drug treatment
(as some glucose-lowering drugs are associated with both
body weight and mortality [47]) and smoking, which is
negatively correlated with BMI and positively with mortality
[48, 49]. This association is conditioned on the effect of
Studies included in the
quantitative synthesis
N=21
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- Not relevant outcomes 8
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38,545 records removed




3 additional articles identified
from manual search of
reference lists
Cardiovascular disease mortality
7 studies | 7 cohorts
All-cause mortality
19 studies | 22 cohorts
Fig. 1 Study flow diagram in line
with Preferred Reporting Items
for Systematic Reviews and
Meta-Analyses (PRISMA)
recommendations
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having diabetes such that the inverse association between
smoking and BMI is exaggerated, which may potentially lead
to an underestimation of the mortality risk associated with
obesity. This may result in a collider bias, requiring detailed
adjustment for smoking [50]. Almost all studies included in
the meta-analysis, however, adjusted for smoking status. We
were unable to conduct a stratified analysis by smoking status
as only two studies reported the risk of mortality by BMI
separately for each smoking category. Zhao and colleagues
found that the risk estimates for different BMI groups
compared with a reference group (30–34.9 kg/m2) were
slightly higher in never smokers in comparison with current
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Fig. 2 Relationship between BMI and all-cause mortality for (a) both sexes, (b) men and (c) women. Grey shading indicates 95% CI
244 Diabetologia (2017) 60:240–248
smokers in both Black and White participants [41]. In
comparison Jackson and colleagues did not find a variation
in the association between BMI and mortality by smoking
status [30].
Our findings showed a nonlinear relationship between BMI
and all-cause mortality in people with diabetes, with the
lowest risk around 33 kg/m2. This is in line with a large
meta-analysis of 141 studies assessing the association
between BMI and mortality in the general population which
found a 6% statistically significant reduction in mortality risk
associated with being overweight (BMI 25–30 kg/m2), a 5%
non-significant reduction associated with being modestly
obese (BMI 30–35 kg/m2), and a 29% increase in the risk
associated with a BMI of over 35 kg/m2 when compared with
normal weight (BMI 18–25 kg/m2) [3]. In contrast, a recent
dose–responsemeta-analysis assessing the relationship in type
2 diabetes reported a progressive linear 5% reduction of
all-cause mortality for every 5 kg/m2 increase in the BMI
(six studies and eight cohorts) [13]. However, this
meta-analysis also included studies reporting on populations
with pre-existing cardiovascular morbidities, such as heart
failure [51, 52], whilst some large population-based studies
were omitted.Moreover, in view of previous knowledge about
the shape of the association between BMI and mortality in the
general population, we did not assume the dose–response
relationship to be linear and did not use conventional BMI
categories but rather investigated possible nonlinearity in the
BMI–mortality association. This enabled us to clarify the
shape of the association across a wide range of BMI and assess
whether there was a significant departure from linearity and a
difference between male and female participants. Our results,
indeed, clearly showed a nonlinear relationship for all-cause
mortality, whilst the association with cardiovascular mortality
is less clear (and potentially linear). We found, in particular,
the mortality curve to be steeper in women compared with
men, with a considerably higher risk of mortality at higher
BMIs in women thanmen, and the nadir to be lower in women
than men. Of note, in the sensitivity analysis excluding studies
reporting unadjusted estimates, the risk for higher BMI was
less pronounced: whether this is relates to a reduced statistical
power or a true effect could not be ascertained. However, our
findings are line with a general population study including
over 12 million adults from South Korea, which found the
optimal BMI for women to be lower than men, especially at
younger ages [53]. This may be attributed to a positive and
strong association between obesity and sex-specific cancer
incidence and mortality in women [54–57].
The progressively increasing risk of all-cause mortality for
values of BMI ≤25 kg/m2 in both men and womenmay have a
number of explanations. Sarcopenic obesity is a condition
characterised by relative increase in fat mass and reduction
in muscle mass, thus resulting in a different total body fat
composition for the same weight (and therefore BMI).
Typically, people with sarcopenic obesity have visceral fat
accumulation [58], a well-known risk factor for cardiovascular
mortality [46]. The prevalence of sarcopenic obesity has been
reported to be higher in type 2 diabetes compared with
non-diabetes (15.7% vs 6.9% respectively in the Korean
Sarcopenic Obesity Study) [59] and it has also been linked to
an increased risk of falls [59], physical disability [60] and
cardiovascular and all-cause mortality [61–64]. Another
possible explanation could be reverse causation. Underlying
conditions may result in loss of appetite or increased metabolic
demands with subsequent unintentional weight loss. This
phenomenon has been reported to be stronger in people with
diabetes as they have higher rates of underlying illness
compared with the general population [50]. This may partly
explain the shape of association in our meta-analysis, with an
increased risk for low values of BMI. In this analysis we were
able to include data from eight studies that excluded the initial
2 years of follow-up to reduce the risk of reverse causation. A
third possible reason is genetics. Some single nucleotide poly-
morphism (SNP) variants are more strongly associated with
type 2 diabetes in lean compared with obese subsets [65].
Among such SNPs, variants at TCF7L2 and CDKAL1 have
also been associated with increased risk of cancer in
people with diabetes [66], potentially explaining the higher
mortality risk for low BMI values. However, stronger evidence
(ideally with Mendelian randomisation studies) is needed to
support a genetic explanation in people with diabetes. Finally,
potentially improved diagnosis and care of obese people with
type 2 diabetes (i.e. screen-detected diabetes, more intensive
control of risk factors) is another plausible explanation [67].
Conclusion Findings from this meta-analysis of prospective
cohort studies demonstrated a nonlinear relationship between
BMI and all-cause mortality, with lower risks between 31 and
35 kg/m2 for men and 28 and 31 kg/m2 for women. Further
research is needed to decipher whether this association is truly
causal and different from that between BMI and cardiovascular
mortality. Furthermore, to better clarify the link between excess










Fig. 3 Relationship between BMI and cardiovascular mortality (both
sexes). Grey shading indicates 95% CI
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(including overall and region-specific body fat accumulation)
over time are warranted. The results of our study, along with
available previous knowledge in this field, do not downgrade
the importance of weight control and appropriate lifestyle
as cornerstones for the prevention and management of
cardiometabolic diseases.
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